Testing a new medication against standard treatment for a rare blood cancer

Plain-English translation of NCT07033598 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether a new medication called works better than , a standard treatment, for advanced chronic myelomonocytic leukemia (a rare blood cancer). About 66 people will be randomly assigned to receive either or for up to 48 weeks, and researchers will track how well the medication works and its side effects.

This medication is being studied because doctors need better treatment options for people with advanced forms of this rare blood cancer. Current treatments like don't work well enough for everyone, so researchers want to see if this new approach can help more patients.

Do you qualify?

You likely qualify if…

you have been diagnosed with chronic myelomonocytic leukemia with specific characteristics (less than 10% immature cells in bone marrow)
you have elevated white blood cell counts and signs of advanced disease (such as an enlarged spleen, low platelet count, or a specific symptom score)
you are generally able to care for yourself with minimal assistance (ECOG performance status of 2 or better)
your organs (liver, kidneys, heart) are functioning well enough to handle the medication
you are willing to use reliable birth control during the study and for 90 days after treatment ends

You likely don't qualify if…

you have had another active cancer diagnosed in the past 2 years (except for very early skin cancers or stable prostate cancer)
you have received a bone marrow transplant in the past year or are planning to have one soon
you have previously taken a JAK inhibitor medication
you have serious bleeding problems or are taking blood-thinning medications (except low-dose aspirin)
you have uncontrolled heart problems, active infections, or serious liver disease

What participation looks like

If you join this trial, you'll visit a research center for screening (about 28 days), then be randomly assigned to take either the new medication (twice daily) or the standard treatment for up to 48 weeks. You'll have regular check-ins and blood tests to monitor how you're doing. Even if you stop the study medication early, researchers will follow up with you for about a year to track your health and survival.

AI-generated summary from trial data · Jun 27, 2026 · Not medical advice

Trial locations(4 sites)

United States

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute at Emory, Atlanta, Georgia

Mayo Clinic Rochester, Rochester, Minnesota

MD Anderson Cancer Center, Houston, Texas